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In this article, we report a convenient and efficient method for the synthesis of new simplified derivatives 
of hemiasterlin in which the α,α-dimethylbenzylic moiety A is replaced by α,β-unsaturated aryl groups as 
Michael acceptor. Most of these derivatives have a strong cytotoxic activity on three human tumor cell 
lines (KB, Hep-G2 and MCF7). Analogs 17b and 17f showed a high cytotoxicity against KB and Hep-G2 
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potent cytotoxicity against 
KB cell line with IC50 up to 3.5 nM  
 
 
Hemiasterlins belong to a family of naturally occurring tripeptides from marine sponges.1 The important 
derivatives of hemiasterlins are hemiasterlin A, hemiasterlin B, and hemiasterlin C, which were isolated 
from marine sponge Auletta and Cymbastella (Fig. 1) and exhibited potent cytotoxicity in vitro against 
murine leukemia P388 and human breast, ovarian, colon, and lung cancer cell lines.2,3 Hemiasterlins 
suppress microtubule depolymerization presumably by binding to the vinca-alkaloid binding-domain of 
tubulin and leading to mitotic arrest and cell death.4a The synthetic analog HTI-286 (2) displayed especially 
potent cytotoxicity against paclitaxel (TaxolTM) resistant turmor cell lines in vitro and in vivo and is 




















































2 (HTI-286              R = H)















Figure 1. Structures of hemiasterlin derivatives and HTI analogs. 
 
There are several reports on the synthesis of new derivatives of hemiasterlin in which the indole aromatic 
ring in the moiety A of the original molecule was replaced by aryl functional groups.5,6a However, 
asymmetric synthesis of the stereospecific amine group and especially the gem-dimethyl moiety were 
proved to be highly problematic. To overcome this difficulty, several studies explored modifications of 
segment A in which the gem-dimethyl moiety has been eliminated. Some of these derivatives showed 
promising cytotoxic activity.6 
In recent years, previous works have shown that the presence of a α,β-unsaturated carbonyl system in 
peptide derivatives can improve the biological activity compared to the initial compound.7,8 Explanations 
may include either a limitation of free energy of the peptide by addition of a constrained system or by an 
electrophilic character of the compound leading to the possibility to form covalent bond with the protein 
target. Based on the idea that hemiasterlin derivatives containing α,β-unsaturated carbonyl systems could 
induce a remarkable cytotoxicity, we decided to synthesize new hemiasterlin derivatives in which the α,α-
dimethylbenzylic group (fragment A) is replaced by a α,β-unsaturated carbonyl group. 
New hemiasterlin derivatives were synthesized via classical peptide coupling reactions between two 
fragments 7a-h and 14a,b. A general procedure for the synthesis of compound 7 is outlined in Scheme 1. 
Compounds 7 were prepared from glycine in three steps.9 The synthesis started by acetylation of glycine 
with acetic anhydride in water at room temperature following by condensation with aryl aldehydes using 
sodium acetate in the presence of acetic anhydride at 90 °C for 12 h which afforded azalactones 6a-h in 72-
83% yields.9 Finally, azalactones 6a-h were hydrolyzed in aqueous sodium hydroxide, followed by 





6a Ar = naphthan-2-yl  
6b Ar = furan-2-yl 
6c Ar = furan-3-yl  
6d Ar = thiophen-3-yl  
6e Ar = 3-methoxyphenyl
6f Ar = 4-methoxyphenyl
6g Ar = 4-bromophenyl
6h Ar = 3-bromophenyl
7a, 82% - 7b, 80% - 7c, 75%
7d, 65% - 7e, 85% - 7f, 83%
7g, 88% - 7h, 87%

































Scheme 1. Reagents and conditions (i) 2.0 equiv Ac2O, H2O, rt, 20 h. (ii) 0.75 equiv ArCHO, 1.0 equiv AcONa, 












Compounds 14a,b were obtained from Boc-L-valine in 6 steps as depicted in Scheme 2.4 In the first step, 
Boc-L-valines 8a,b were converted to Weinreb amide 9a,b in good yields (86 and 81%) by treatment with 
a mixture of N,O-dimethylhydroxylamine hydrochloride, 1-ethyl-3-(3-dimethylaminoproryl)carbodiimide 
(EDC) and hydroxybenzotriazole (HOBt) in the presence of N-ethylisopropylamine (i-PrNHEt) at room 
temperature for 12 h.10 Reduction of 9a,b using LiAlH4 in THF was carried out at room temperature for 1 h 
to give aldehydes 10a,b in 78% and 65% yields, respectively.11 Afterward, Wittig reaction of aldehydes 
10a,b with ethyl 2-(triphenylphosphoranylidene)propanoate was carried out at reflux in CH2Cl2 for 6 h to 
afford the alkenoates 11a and 11b in 86% and 88% yields, respectively.6,12 Then, removal of the Boc group 
using trifluoroacetic acid in CH2Cl2 at room temperature for 1 h led to 12a,b in high yields (90 and 95%). 
The expected compounds 14a,b are finally obtained after coupling 12a,b and Boc-L-leucine in the presence 















15a, 60% - 15b, 50% - 15c, 55%
15d, 75% - 15e, 70% - 15f, 65%
15g, 71% - 15h, 60%
16a, 90% - 16b, 94% - 16c, 90%
16d, 98% - 16e, 90% - 16f, 95%











17a, 70% - 17b, 73% - 17c, 67%
17d, 86% - 17e, 65% - 17f, 68%
17g, 70%
18a, 94% - 18b, 98% - 18c, 92%






































Scheme 2. Reagents and conditions (i) 1.1 equiv NH(Me)OMe.HCl, 1.1 equiv EDC, 1.1 equiv HOBt, 2.0 equiv i-
PrNHEt, DMF, rt, 12 h. (ii) 4.0 equiv LAH, THF, rt, 1 h. (iii) Ph3P=C(CH3)CO2Et, CH2Cl2, reflux, 6 h. (iv) TFA, 
CH2Cl2, rt, 1 h. (v) 1.0 equiv Boc-L-Leucine, 1.1 equiv EDC, 1.1 equiv HOBt, 2.0 equiv i-PrNHEt, DMF, rt, 12 h. 
(vi) TFA, CH2Cl2, rt, 1 h. 
 
The final compounds 16a-h were then prepared in two steps after peptide coupling reactions of 14a with 
amides 7a-h following by the saponification of ester using a 1 N lithium hydroxide solution (Scheme 3-a). 
Similarly, the hemiasterlin derivatives 18a-g were obtained from 14b (Scheme 3-b). 
All compounds 15a-h, 16a-h, 17a-g and 18a-g were evaluated in vitro for their cytotoxic activity against 
four human tumor cell lines (KB, Hep-G2, LU and MCF7) and the results were summarized in Table 1.  
Eleven hemiasterlin derivatives showed strong activity against the KB, Hep-G2 cell line with IC50 value 
below 100 nM. Analogs 16b, 17b and 18f exhibited potent cytotoxicity against the KB cell line with IC50 = 
8.2, 3.5 and 3.7 nM, respectively. Meanwhile analogs 16b, 2217c and 17f displayed potent cytotoxicity 
against the Hep-G2 cell line with IC50 value 17.8, 16.3 and 3.7 nM, respectively. Derivatives 15a, 15e and 
17a presented a cytotoxic activity against MCF7 cell line with IC50 value 42.3, 60.0 and 67.9 nM. 
Concerning the last cell line, the LU cell line, the hemiasterlin analogs showed weak activities with IC50 
values above 269 nM. It is noteworthy to mention that two derivatives 17a and 17f present a cytotoxic 































9a R=H    (86%) 
9b R=Me (81%)
R R R
11a R=H   (86%) 
11b R=Me (88%)
R
12a R=H   (90%) 
12b R=Me (95%)
13a R=H    (73%) 
13b R=Me (74%)
RR

























Scheme 3. Reagents and conditions (i) 1.0 equiv 7a-h, 1.1 equiv EDC, 1.1 equiv HOBt, 2.0 equiv i-PrNHEt, DMF, 












































KB Hep-G2 LU MCF7 
1 15a 30.8 39.7 >269 42.3 
2 15b 160.5 214.2 >269 >269 
3 15c 86.2 67.3 >269 >269 
4 15d 107.4 57.6 >269 203 
5 15e 77.4 47.7 228.4 62 
6 15f >269 >269 >269 >269 
7 15g >269 >269 >269 >269 
8 15h >269 >269 >269 >269 
9 6a 63 33.4 >269 >269 
10 6b 8.2 17.8 >269 >269 
11 6c 155.4 >269 >269 >269 
12 6d >269 >269 >269 >269 
13 6e >269 >269 >269 >269 
14 6f >269 >269 >269 >269 
15 6g >269 >269 >269 >269 
16 6h >269 >269 >269 >269 
17 17a 23.0 23.1 >269 67.9 
18 17b 3.5 31.4 231.0 178.4 
19 17c 24.1 16.3 158 112.8 
20 17d 202 15.0 >269 >269 
21 17e >269 >269 >269 >269 
22 17f 3.7 3.7 >269 215 
23 17g 49.0 >269 >269 >269 
24 18a 69.7 13.0 >269 >269 
25 18b 188.0 >269 >269 >269 
26 18c >269 149.4 >269 >269 
27 18d 234 63.2 >269 >269 
28 18e >269 >269 >269 >269 
29 18f 15.8 63.8 >269 >269 
30 18g >269 >269 >269 >269 
31 Ellipticine 1.26 1.26 1.82 2.15 

















In conclusion, a concise synthetic approach for new modified hemiasterlin derivatives was achieved in 
which the α,α-dimethylbenzylic group and amino NHMe moiety were replaced respectively by a α,β-
unsaturated aryl and an amide NH-Ac group avoiding the synthesis of the chiral fragment A. Most of these 
derivatives possess strong cytotoxic activity on three human tumor cell lines (KB, Hep-G2 and MCF7) and 
two analogs, 17b and 17f, showed a comparable cytotoxicity activity to paclitaxel and ellipticine against 
KB and Hep-G2 cancer cell lines. Based on previously reported work,6b we can envisage that our 
hemiasterlin derivatives act as tubulin polymerization inhibitors. From our best compounds, more detailed 
biological studies will be undertaken and will be reported in due course. 
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